Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.34 |
| ▸ | UBE2M | P61081 | 1/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13807749 | 0.92 | FAAH (0.38) | FAAHUBE2MDCUN1D1LMNAHSD11B1 | |
| SCHEMBL4320850 | 0.88 | MAPT (0.34) | UBE2MDCUN1D1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4326526 | 0.87 | UBE2M (0.33) | UBE2MDCUN1D1LMNA | |
| SCHEMBL13807750 | 0.83 | FAAH (0.38) | FAAHUBE2MDCUN1D1LMNAHSD11B1 | |
| SCHEMBL13807629 | 0.82 | CCR1 (0.33) | FAAHUBE2MDCUN1D1SPRALDH1A1 | |
| SCHEMBL13807668 | 0.81 | TP53 (0.33) | UBE2MDCUN1D1LMNAALDH1A1 | |
| SCHEMBL13807677 | 0.80 | UBE2M (0.32) | FAAHUBE2MDCUN1D1LMNAALDH1A1 | |
| SCHEMBL13807216 | 0.77 | HTT (0.46) | FAAHALDH1A1F2RL3 | |
| SCHEMBL4312441 | 0.77 | ALDH1A1 (0.35) | UBE2MDCUN1D1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13807626 | 0.75 | FAAH (0.34) | FAAHUBE2MDCUN1D1SPRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | claimed |
| EP-1957076-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | claimed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| EP-1957076-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CX3CR1 | FAAH 2880/4885UBE2M 4847/4885DCUN1D1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.